Most Popular Stories
- FDA maps out long-awaited rules for the biosimilars business
- FDA approvals of 2011
- Mouse study triggers demands for a possible Alzheimer's treatment
- High price of failure drives drug development costs into the stratosphere
- GSK, Takeda say nay to in-house diagnostics units
- Eisai loses panel vote on new Dacogen use
Webinars
- Inside the mHealth Revolution with Welch Allyn: Realizing the Potential of Connected DevicesAfter launching a line of connected devices, Welch Allyn immediately viewed it as an oppor
- Webinar: Next Gen Sequencing from FFPE SamplesNext generation sequencing (NGS) technologies hold enormous promise to advance personalize
- Biomarkers and Translational Medicine in Early Phase Oncology Clinical Development (Part two of our three part series) Increasingly, new technologies are making it possible to carefully identify sets of patien
- Getting the most out of First-in-Human and Early Clinical TrialsIn a follow-up to our webinar last month on first-in-human drug studies, FierceBiotech edi
Featured Jobs
-
Director Marketing Communications
Bailey Search & Associates - Boston, MA -
Sr. Director, Alliance Management Job
Celgene Corporation - Summit, NJ, US -
Benefits Specialist Job
Celgene Corporation - Summit, NJ, US -
Product Manager, Channel Marketing Job
Celgene Corporation - Summit, NJ, US -
District Sales Manager – Hematology, Denver / Phoenix Job
Celgene Corporation - Denver, CO, US
Popular Topics
Events
- DCAT Week '12 Biologics Forum & Networking Reception
Mar 14 — New York City - CALBIO2012: Driven By Patients - Marriott Marquis
March 8-9 — San Francisco, CA - Pharmaceutical Strategic Outlook
April 11-13, 2012 — Grand Hyatt, New York - Pharmaceutical Strategic Outlook
April 11-13, 2012
Image: AstraZeneca CEO David Brennan
Tools
AstraZeneca CEO David Brennan


SHARE
WITH: